Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest update is out from Oncopeptides AB ( (SE:ONCO) ).
Oncopeptides AB announced the upcoming release of its Q1 2025 financial report, scheduled for May 15, 2025. The company will host a webcast and Q&A session for investors, analysts, and media, led by CEO Sofia Heigis and CFO Henrik Bergentoft. This event provides stakeholders an opportunity to gain insights into the company’s financial performance and strategic direction.
More about Oncopeptides AB
Oncopeptides AB is a Swedish biotech company specializing in the development and commercialization of targeted therapies for difficult-to-treat cancers. Utilizing its proprietary Peptide Drug Conjugate platform, the company creates compounds that deliver cytotoxic agents directly into cancer cells. Its flagship drug is being commercialized in Europe, with partnerships in South Korea, the Middle East, and Africa. Founded in 2000, Oncopeptides operates in several European countries and is listed on Nasdaq Stockholm.
Average Trading Volume: 907,426
Current Market Cap: SEK394.2M
For an in-depth examination of ONCO stock, go to TipRanks’ Stock Analysis page.